• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Akari Therapeutics plc (Amendment)

    2/14/23 4:05:33 PM ET
    $AKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTX alert in real time by email
    SC 13G/A 1 ea173418-13ga4patel_akari.htm AMENDMENT NO. 4 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

     

     

    Akari Therapeutics, PLC

    (Name of Issuer)

     

    Ordinary Shares, par value $0.0001 per share

    (represented by American Depositary Shares)

    (Title of Class of Securities)

     

    00972G108

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 00972G108 SCHEDULE 13G Page 2 of 5

     

    1

    NAME OF REPORTING PERSON

     

    Samir R. Patel

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) ☐

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES

    BENEFICIALLY

    OWNED BY

    EACH
    REPORTING PERSON
    WITH

    5

    SOLE VOTING POWER

     

    7,862,047 shares(1)

    6

    SHARED VOTING POWER

     

    0 shares

    7

    SOLE DISPOSITIVE POWER

     

    7,862,047 shares(1)

    8

    SHARED DISPOSITIVE POWER

     

    0 shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    7,862,047 shares(1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    9.9%

    12

    TYPE OF REPORTING PERSON

     

    IN

     

     

    (1)Comprised of Ordinary Shares represented by American Depositary Shares. Each American Depositary Share reported represents 100 Ordinary Shares. Includes warrants to purchase up to 2,238,748 American Depositary Shares. Does not include warrants to purchase up to 2,011,252 American Depositary Shares which are not exercisable within the next 60 days and for which the reporting person disclaims beneficial ownership.

     

     

     

     

    CUSIP No. 00972G108 SCHEDULE 13G Page 3 of 5

     

    Item 1(a). Name of Issuer

     

    Akari Therapeutics, PLC (the “Issuer”)

     

    Item 1(b). Address of Issuer’s Principal Executive Offices

     

    75/76 Wimpole Street

    London W1G 9RT

    United Kingdom

     

    Item 2(a). Name of Person Filing

     

    Samir R. Patel (the “Reporting Person”)

     

    Item 2(b). Address of Principal Business Office or, if None, Residence

     

    The address of the principal business and principal office of the Reporting Person is:

     

    1701 Chicon St., Austin, Texas, 78702

     

    Item 2(c). Citizenship

     

    Samir R. Patel is a citizen of the United States.

     

    Item 2(d). Title of Class of Securities

     

    Ordinary Shares, par value $0.0001 per share (represented by American Depositary Shares, each of which represents 100 Ordinary Shares)

     

    Item 2(e). CUSIP Number

     

    00972G108

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
      (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

     

     

     

    CUSIP No. 00972G108 SCHEDULE 13G Page 4 of 5

     

      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
           
      (j) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership

     

    With respect to the beneficial ownership of the Reporting Person, see Items 5 through 11 of the cover pages to this Schedule 13G, which are incorporated herein by reference.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     

     

     

    CUSIP No. 00972G108 SCHEDULE 13G Page 5 of 5

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

      /s/ Samir R. Patel
      Samir R. Patel

     

     

     

     

     

     

    Get the next $AKTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKTX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with deep oncology experience by appointing new Head of Business Development - Oncology BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. "We remain laser focused on becoming a key player in the ADC space and advancing our novel ADC platform built around i

      5/15/25 8:05:00 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

      Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development

      5/1/25 8:45:00 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

      Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video here BOSTON and LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced the release of a corporate update video featuring newly appointed President and Chief Executive Officer, Abizer Gaslightwala. The video is now available on the Presentations page under the Investors section of the Company's website (www.akaritx.com). About Akari Therapeutics Akari Therapeut

      4/22/25 9:05:00 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKTX
    SEC Filings

    See more
    • Akari Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Akari Therapeutics Plc (0001541157) (Filer)

      5/15/25 8:58:09 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Akari Therapeutics plc

      EFFECT - Akari Therapeutics Plc (0001541157) (Filer)

      5/15/25 12:15:10 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Akari Therapeutics plc

      10-Q - Akari Therapeutics Plc (0001541157) (Filer)

      5/14/25 4:51:05 PM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

      SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

      12/6/24 4:00:28 PM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Akari Therapeutics plc

      SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)

      6/20/24 7:30:07 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Akari Therapeutics plc

      SC 13D - Akari Therapeutics Plc (0001541157) (Subject)

      6/18/24 4:15:30 PM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patel Sandip I was granted 44,642 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 10% to 496,499 units (SEC Form 4)

      4 - Akari Therapeutics Plc (0001541157) (Issuer)

      4/29/25 5:00:12 PM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bazemore Robert B

      4 - Akari Therapeutics Plc (0001541157) (Issuer)

      3/24/25 5:00:15 PM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Neal James R

      4 - Akari Therapeutics Plc (0001541157) (Issuer)

      3/24/25 5:00:16 PM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKTX
    Financials

    Live finance-specific insights

    See more
    • Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

      BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this

      11/8/24 8:00:00 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

      BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be

      10/15/24 8:00:00 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders

      Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen

      6/5/24 8:00:00 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AKTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

      Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development

      5/1/25 8:45:00 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akari Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

      Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC candidates across a range of solid/hematological cancers Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline Cash on hand expected to be sufficient to fund planned operations into September 2025 BOSTON and LONDON, April 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-fun

      4/16/25 8:00:00 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

      Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several executive leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVA®, Repatha®, and ELIQUIS® Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company's Board of Directors BOSTON and LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a biotechnology company developing next-generation preci

      3/20/25 8:35:00 AM ET
      $AKTX
      Biotechnology: Pharmaceutical Preparations
      Health Care